Clinical trials: Hospitalized COVID-19
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
COVID-19, Comorbidities and Coexisting Conditions
Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study
This is a two-phase multicenter study that will be conducted in collaboration with five university hospitals, in order to offer telehealth services at home in patients with COVID-19, after hospital discharge.
- Trial name
- ATHLOS (NCT04368845)
- Testing
- Telerehabilitation
- Where
- Greece
- Volunteers
- 82 people
- Sponsor
- University of Thessaly
History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19.
- Trial name
- ACORES-2 (NCT04329195)
- Testing
- 1: discontinuation of RAS blocker therapy, 2: continuation of RAS blocker therapy
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Covid19
Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients
The SaiseiCovUKR clinical study is a multicentric, randomized trial study targeting patients hospitalized with COVID-19 who do not require mechanical ventilation.
- Trial name
- SaiseiCovUKR (NCT04762628)
- Testing
- MAF capsules 148 mg, M capsules 148 mg, Standard of care
- Where
- 2 sites in Ukraine
- Volunteers
- 600 people
- Sponsor
- Saisei Pharma
Sars-CoV-2, Covid19
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability…
- Trial name
- NCT04334460
- Testing
- BLD-2660
- Where
- 35 sites in United States, Brazil
- Volunteers
- 120 people
- Sponsor
- Blade Therapeutics
COVID-19
Epidemiological Monitoring of COVID-19 Patients Hospitalized on Reunion Island
The island of Reunion, a French overseas department of 860,000 inhabitants, located in the Indian Ocean (OI) zone, recorded its first case of COVID-19 on March 11, 2020.
- Trial name
- COVIDEPI-SUIV' (NCT05413694)
- Testing
- telephone interview 24 months after hospitalization for Covid-19
- Where
- Reunion
- Volunteers
- 450 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Coronavirus Infections
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The aim of this study is to analyze if administration of conestat alfa for 72 hours in addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) reduces…
- Trial name
- NCT04414631
- Testing
- Conestat alfa
- Where
- 5 sites in Brazil, Mexico and 1 more
- Volunteers
- 80 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19, Palliative Care
Palliative Care in Patients With COVID-19: Analysis of Costs of Hospitalization in Wards and Intensive Care Units
The confrontation of COVID-19 foreshadowed a serious crisis of scarce health resources worldwide. To assist in this confrontation, the Palliative Care Scientific Technical Core of the Clinical Hospital, School of Medicine, Sao…
- Trial name
- NCT05897229
- Testing
- Analysis of costs with patient care during hospitalization
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo General Hospital
Coronavirus Infections
Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong
COVID-19 may cause another world-wide epidemic. This study is divided into 2 arms: (1) Prospective longitudinal observational study involving patients with laboratory-confirmed COVID-19 and (2) Retrospective study on patients…
- Trial name
- NCT04325919
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 170 people
- Sponsor
- Chinese University of Hong Kong
SARS-COV2
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive…
- Trial name
- NICOVID (NCT04608201)
- Testing
- Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronavirus Infection, Pneumonia, Viral
Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) is a rapidly spreading infection of the respiratory tract. Most infected patients have either asymptomatic disease or mild symptoms.
- Trial name
- SPIDEX-II (NCT04826822)
- Testing
- Spironolactone + Dexamethasone, Standard-of-care SARS-CoV-2 treatment
- Where
- Russia
- Volunteers
- 440 people
- Sponsor
- Chita State Regional Clinical Hospital Number 1
Acute Respiratory Distress Syndrome, Coronavirus Infection
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04478071
- Testing
- vadadustat
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- The University of Texas Health Science Center, Houston
COVID-19
Effectiveness and Safety of Quinine Sulfate as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia ( DEAL-COVID19 )
This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of Quinine Sulfate as an add-on therapy in hospitalized adults with COVID-19.
- Trial name
- DEAL-COVID19 (NCT05808231)
- Testing
- Standard of Care + Quinine Sulfate, Standard of Care
- Where
- 2 sites in Indonesia
- Volunteers
- 100 people
- Sponsor
- Universitas Padjadjaran
Confirmed Coronavirus Disease
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e.
- Trial name
- NCT04530136
- Testing
- Ruconest
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pharming Technologies B.V.
Sars-CoV2
REassessement After Hospitalization for Sars-COV-2 disordER
Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described.
- Trial name
- REHCOVER (NCT04443257)
- Testing
- assessment of the sequelae after hospitalization for Sars-COV-2
- Where
- France
- Volunteers
- 119 people
- Sponsor
- University Hospital, Montpellier
COVID, Pneumonia, Viral
Anti Infective Agents Impact in COVID-19 Pneumonia
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al.
- Trial name
- AZITHROVID (NCT04453501)
- Testing
- favorable outcome
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
COVID, COVID-19
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure.
- Conditions
- COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- NCT04546581
- Testing
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Remdesivir
- Where
- 39 sites in United States, Denmark and 5 more
- Volunteers
- 593 people
- Sponsor
- University of Minnesota
COVID-19 Infection
An Open-Label Study of Apabetalone in Covid Infection
The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection
- Trial name
- NCT04894266
- Testing
- Apabetalone, Standard of care
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Resverlogix Corp
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization
The principal aim of this interventional, multicentre study is to compare the impact of a follow-up by monthly telephone dietetic consultations, started 3 months after discharge from hospital, for a period of 3 months, on the…
- Trial name
- COVINUT (NCT04933929)
- Testing
- Post-hospitalization nutritional monitoring
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Gérond'if